RecruitingPhase 1NCT05005403
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Azirkitug(drug)
- Enrollment
- 694 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- City of Hope National Medical Center /ID# 276272, Duarte, California, United States
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne, Indiana, United States
- Community Health Network, Inc. /ID# 243011, Indianapolis, Indiana, United States
- Norton Cancer Institute /ID# 248903, Louisville, Kentucky, United States
- START Midwest /ID# 248685, Grand Rapids, Michigan, United States
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha, Nebraska, United States
- Carolina BioOncology Institute /ID# 232597, Huntersville, North Carolina, United States
- NEXT Oncology Austin /ID# 243005, Austin, Texas, United States
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston, Texas, United States
- NEXT Oncology /ID# 243007, San Antonio, Texas, United States
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio, Texas, United States
- Start Mountain Region /ID# 276270, West Valley City, Utah, United States
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax, Virginia, United States
- The Chaim Sheba Medical Center /ID# 238332, Ramat Gan, Tel Aviv, Israel
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05005403 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital